Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation

Lee, Wen-shin; Erdélyi, Katalin; Mátyás, Csaba; Mukhopadhyay, Partha; Varga, Zoltán V.; Liaudet, Lucas; Haskó, György; Čiháková, Daniela; Mechoulam, Raphael; Pacher, Pál

doi:10.2119/molmed.2016.00007

Cited by 63 publications

(41 citation statements)

References 50 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…125 There was also decreased expression of F4/80 (a marker of macrophages) mRNA expression by CBD in heart tissue in experimental autoimmune myocarditis. 126 Although this study identified CBD only affecting F4/80 mRNA expression as opposed to F4/80 cell surface staining, it does suggest a novel target (i.e., heart tissue) of CBD in a relatively understudied autoimmune model. IL-6 is a proinflammatory cytokine produced by many cell types, predominantly innate cells.…”

Section: Cbd Effects and Mechanisms Of Immune Suppression In Innate Cmentioning

confidence: 63%

Immune Responses Regulated by Cannabidiol

Nichols

Kaplan

2020

Cannabis and Cannabinoid Research

198

176

View full text Add to dashboard Cite

Introduction: Cannabidiol (CBD) as Epidiolex Ò (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and immune suppressive, so the purpose of this review is to summarize effects and mechanisms of CBD in the immune system. It includes a consideration of reports identifying receptors through which CBD acts, since the ' 'CBD receptor,' ' if a single one exists, has not been definitively identified for the myriad immune system effects. The review then provides a summary of in vivo and in vitro effects in the immune system, in autoimmune models, with a focus on experimental autoimmune encephalomyelitis, and ends with identification of knowledge gaps. Conclusion: Overall, the data overwhelmingly support the notion that CBD is immune suppressive and that the mechanisms involve direct suppression of activation of various immune cell types, induction of apoptosis, and promotion of regulatory cells, which, in turn, control other immune cell targets.

show abstract

Section: Cbd Effects and Mechanisms Of Immune Suppression In Innate Cmentioning

confidence: 63%

Immune Responses Regulated by Cannabidiol

Nichols

Kaplan

2020

Cannabis and Cannabinoid Research

198

176

View full text Add to dashboard Cite

show abstract

“…Indeed, CBD has been suggested as a promising treatment also for autoimmune myocarditis and possibly other autoimmune disorders, and it might be useful for organ transplantation (466). Very recently, the positive results of a phase II study that assessed the safety and efficacy of CBD in the prevention of acute graft-versus-host-disease were reported (931).…”

Section: Pain Inflammation Autoimmunity and Retinal Diseasesmentioning

confidence: 99%

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

Ligresti¹,

Petrocellis²,

Marzo³

2016

Physiological Reviews

365

337

View full text Add to dashboard Cite

Apart from having been used and misused for at least four millennia for, among others, recreational and medicinal purposes, the cannabis plant and its most peculiar chemical components, the plant cannabinoids (phytocannabinoids), have the merit to have led humanity to discover one of the most intriguing and pleiotropic endogenous signaling systems, the endocannabinoid system (ECS). This review article aims to describe and critically discuss, in the most comprehensive possible manner, the multifaceted aspects of 1) the pharmacology and potential impact on mammalian physiology of all major phytocannabinoids, and not only of the most famous one ⌬ 9 -tetrahydrocannabinol, and 2) the adaptive prohomeostatic physiological, or maladaptive pathological, roles of the ECS in mammalian cells, tissues, and organs. In doing so, we have respected the chronological order of the milestones of the millennial route from medicinal/recreational cannabis to the ECS and beyond, as it is now clear that some of the early steps in this long path, which were originally neglected, are becoming important again. The emerging picture is rather complex, but still supports the belief that more important discoveries on human physiology, and new therapies, might come in the future from new knowledge in this field.

show abstract

“…Studies have indicated a variability in policies regarding appropriateness of marijuana use in transplant recipients, even differing between organ programs within the same institutions. Programs have delayed access to transplantation by requiring discontinuation of marijuana use for arbitrary periods of time ranging from 3 to 6 months . Screening potential transplant candidates needs to take into account the long half‐life of marijuana.…”

Section: Resultsmentioning

confidence: 99%

Marijuana use in transplantation: A call for clarity

Levi¹,

Montague²,

Thurstone

et al. 2019

Clinical Transplantation

View full text Add to dashboard Cite

Transplant centers have varying policies for marijuana (MJ) use in donors, transplant candidates, and recipients. Rationales for these differences range from concerns for fungal complications, impaired adherence, and drug interactions. This paper reviews the current status of MJ policies and practices in transplant centers and results of a survey sent to the American Society of Transplantation (AST) membership by the Executive Committee of the AST Infectious Diseases Community of Practice. The purpose of the survey was to compare policies and concerns of MJ use to actual observed complications. Of the 3321 surveys sent, 225 members (8%) responded. Transplant centers varied in their approval processes, differing even in organ types within the same institutions. Furthermore, there was discordance among transplant centers in their perceived risks of marijuana use as opposed to complications actually observed. An increasing number of states continue to legalize medical and recreational MJ resulting in widespread availability. Further research is needed to assess the validity of concerns for complications of MJ use in potential donors and recipients. Ultimately, standardized guidelines should be established based on studies and evidence-based criteria to assist transplant programs in their policies around the use of cannabis in their donors and recipients.

show abstract

Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation

Cited by 63 publications

References 50 publications

Immune Responses Regulated by Cannabidiol

Immune Responses Regulated by Cannabidiol

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

Marijuana use in transplantation: A call for clarity

Contact Info

Product

Resources

About